Thursday, May 26, 2022
  • Hyderabad
  • Telangana
  • Andhra Pradesh
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Reviews
    • Education Today
    • Property
    • Videos
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
Home | Business | Bharat Biotech Gets Dcgis Nod To Conduct Intranasal Booster Dose Trials

Bharat Biotech gets DCGI’s nod to conduct intranasal booster dose trials

By ANI
Published: Updated On - 03:22 PM, Fri - 28 January 22
The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) had also recommended the internasal vaccine clinical trials during the last meeting.

New Delhi: The Drugs Controller General of India (DCGI) on Friday granted permission to Bharat Biotech to conduct clinical trials of intranasal vaccine BBV154.

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) had also recommended the internasal vaccine clinical trials during the last meeting.

The NOC letter issued by the DCGI read, “Central Licensing Authority hereby permits Bharat Biotech International limited to conduct clinical trials of the new drug or investigational new drug.”

The dosage form of the vaccine is liquid for the intranasal route of administration and every single dose contains 0.5ml.

The trials of the Intranasal vaccine will take place at nine different sites of the country.

The trials will be conducted at Atman Hospital, Ahmedabad, Gujarat; AIIMS, Delhi and Patna; Oyster and Pearls Hospitals, Pune; Pt.BD Sharma Postgraduate Institute of Medical Sciences at Rohtak, Haryana; Acharya Vinobha Bhave Rural Hospital, Wardha; Jeevan Rekha Hospital, Belagavi; Rana hospital, Gorakhpur; and Prakhar Hospital, Uttar Pradesh.

“The Phase -3 clinical trial should be conducted as per protocol multi-center study to compare immunogenicity and safety of BBV154 with COVAXIN.” read the letter.

  • Follow Us :
  • Tags
  • Bharat Biotech
  • DCGI
  • dose trials
  • Hyderabad

Related News

  • Hyderabad adopts smart tech for sewage treatment

  • Upset woman ends life in Hyderabad

  • Golf: Boulder Hills Tigers beat Boulder Raiders 2-1 in ATUM T9 Challenge

  • JNTU-Hyderabad to offer dual-degree

  • Hyderabad’s Tilak Varma says playing for MI a great learning experience

  • Telangana to get rail coach unit

Latest News

  • Opinion: Greek lessons for Asean nations

    7 hours ago
  • IPL 2022: Patidar’s 112 not out guides RCB to 14-run win over LSG

    7 hours ago
  • Editorial: Shed ambivalence on caste census

    7 hours ago
  • Using AI to predict heart episodes

    7 hours ago
  • Understanding the functions of male reproductive system

    8 hours ago
  • Telangana’s Anvitha Reddy scales Mt Everest

    7 hours ago
  • Centre turns miser on MGNREGS

    8 hours ago
  • Know the Mulki issue

    8 hours ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam